SLC5A2 and type 2 diabetes mellitus: We investigated whether canagliflozin improved peak VO2 and ventilatory efficiency in patients with T2DM and HFrEF compared to sitagliptin, a dipeptidyl peptidase (DPP)4 inhibitor with proven cardiovascular safety with glucose‐lowering efficacy similar to SGLT2 inhibitors.11